Company intelligence / Profile preview
Vaxiion Therapeutics
San Diego, California, USAvaxiion.com ↗
- Ownership
- Private
- Employees
- ~7
- Development stage
- Other
01
Overview
Vaxiion’s lead product, VAX014—a first-in-class nonviral tumor-targeted oncolytic immunotherapy—is in early-stage clinical trials. It has shown promise as an intratumoral therapy for patients with advanced solid tumors and has also been evaluated in non-muscle invasive bladder cancer. The company’s proprietary recombinant bacterial minicell platform enables targeted delivery of a variety of therapeutic payloads directly to tumor cells.[1][3][6]
- Therapeutic areas
- Oncology
- Modalities
- Bacterial minicell-based delivery systemsOncolytic immunotherapy agentsPotential for small molecules, protein toxins, RNAi, plasmids, peptides, imaging agents[1][6]
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Vaxiion Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vaxiion Therapeutics.